| European Federation of Internal Medicine

New Fee Regulation working arrangements

Submitted by Anonymous (not verified) on 9 July 2024 - 16:06

New Fee Regulation working arrangements

Read more about New Fee Regulation working arrangements

Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 9 July 2024 - 14:43

Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised

Submitted by Anonymous (not verified) on 9 July 2024 - 14:43

Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 9 July 2024 - 14:37

Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised

Submitted by Anonymous (not verified) on 9 July 2024 - 14:20

Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised

Member states contact points for review of national versions of the content of mobile scanning and other technologies

Submitted by Anonymous (not verified) on 9 July 2024 - 14:07

Member states contact points for review of national versions of the content of mobile scanning and other technologies

Read more about Member states contact points for review of national versions of the content of mobile scanning and other technologies

Nitrosamine in vivo mutagenicity workshop, European Medicines Agency, Amsterdam, the Netherlands, from 11 July 2024, 12:00 (CEST) to 12 July 2024, 15:00 (CEST)

Submitted by Anonymous (not verified) on 9 July 2024 - 13:28

Nitrosamine in vivo mutagenicity workshop, European Medicines Agency, Amsterdam, the Netherlands, from 11 July 2024, 12:00 (CEST) to 12 July 2024, 15:00 (CEST)